Revenue segments as reported by the company.

Women’s Health

Biosimilars

Established Brands

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Acquired in-process research and development and milestones

Interest expense

Exchange losses (gains)

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Organon & Co

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organon & Co reports strong Q4 earnings, eyes growth opportunities

Organon & Co's Q4 2022 earnings call highlighted robust financial performance, strategic initiatives in key segments, and a positive outlook for future growth. Despite challenges in China and market dynamics, the company remains focused on leveraging its strengths, addressing challenges, and capitalizing on growth opportunities to drive shareholder value and portfolio expansion.

Organon & Co reports solid Q1 performance and eyes growth opportunities

Organon & Co's Q1 2023 performance reflects revenue growth, margin improvement, and strategic investments in key franchises and medical devices.
The company's strengths lie in financial discipline, strong segment performance, and growth opportunities in fertility markets and biosimilars.
Challenges include inflationary pressures, competitive pricing scenarios, and the need to address loss of exclusivity and pricing dynamics.
Opportunities exist in expanding market presence in Asia Pacific, launching new products, and focusing on sustainable growth through financial prudence.

Organon & Co reports solid Q2 earnings, eyes growth opportunities

Organon & Co's Q2 2023 performance showed revenue growth, margin improvement, and strategic focus on key business segments.
Strengths in product differentiation, market positioning, and growth drivers position the company for continued success.
Challenges in revenue drivers, market expansion, and financial strategy require strategic adjustments for sustained growth.
Opportunities in Women's Health, biosimilar portfolio, and market penetration strategies offer avenues for future growth and market leadership.

Organon reports mixed Q3 results, eyes biosimilar growth opportunities

Organon's Q3 performance showed mixed results with challenges in women's health and biosimilar uptake, but stable growth in established brands.
The company is focusing on cost efficiency, portfolio optimization, and market expansion in biosimilars for future revenue growth.
Despite near-term challenges, Organon remains optimistic about its financial outlook, especially with opportunities in biosimilars and market expansion strategies.
Strategic shifts towards retail sector in China and product optimization are key focus areas for sustained growth and profitability.

Organon & Co reports solid Q4 earnings, eyes strategic growth

Organon's Q4 2023 earnings call showcased strong financials, strategic partnerships, and a focus on cost management. The company aims for low single-digit revenue growth in 2024 and $1 billion in free cash flow.

Organon & Co reports strong Q1 performance, eyes biosimilar growth

Organon & Co's Q1 2024 showcased robust revenue growth and strategic financial planning
Challenges include flat global fertility business and cautious outlook due to foreign exchange dynamics
Opportunities lie in expanding biosimilar market, margin expansion, and transformative deals

Organon & Co reports solid Q2 earnings, eyes franchise growth

Organon & Co's Q2 2024 performance reflects a mix of solid revenue growth and margin stability.
While facing challenges in certain regions and franchise segments, the company maintains a focus on growth.
Strategic opportunities lie in expanding key franchises, regulatory milestones, and operational efficiency.
Overall, Organon & Co remains optimistic about sustained revenue growth and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Organon (OGN) Could Beat Earnings Estimates Again

Organon & Co. (OGN) CEO Kevin Ali on JPMorgan 40th Annual Healthcare Conference (Transcript)

Vimeo

Victoria's Secret & Co

The only two winners were GXO Logistics and DT Midstream. Here's why it can take six months to three years for a spinoff to outperform.

Spinoffs Fared Poorly in 2021 as Victoria's Secret, Vimeo, and Organon Slumped

INCHEON, Korea & JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--FDA Accepts Samsung Bioepis' and Organon's sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate

FDA Accepts Samsung Bioepis' and Organon's sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon CEO and CFO to participate in JP Morgan Conference Fireside Chat

Organon To Present at the 40th Annual J.P. Morgan Healthcare Virtual Conference

STOCKHOLM SWEDEN – December 13, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the previously announced transaction, in which the global pharmaceutical company Organon & Co. (NYSE:OGN) acquires Karolinska Development's portfolio company Forendo Pharma, has now been completed. This is one of the largest commercial deals in the Nordic biotech sector in 2021.

Organon's acquisition of Karolinska Development's portfolio company Forendo Pharma has been successfully completed

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Endometriosis--Organon Announces Close of Forendo Pharma

Organon Completes Acquisition of Forendo Pharma

Organon has seen material share price weakness as of late.

Organon: Too Cheap To Ignore And Set To Soar

Organon fell after posting quarterly results.

Why Buy Organon After Shares Fell Below $30

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, HONG KONG, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS

Karolinska Development AB (publ) proposes a rights issue of approximately SEK 491 million, and publishes a proposal for a new Board member

Evercore

Organon & Co. (OGN) CEO Kevin Ali at 4th Annual Evercore ISI HealthCONx Conference (Transcript)

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1, 2021 at 1:50 p.m. ET. Investors, analysts, members of the media and the general public are invited to watch a live video webcast of the presentation at https://www.organon.com/investor-relations/events-and-presenta

Organon To Present at the Evercore ISI 4th Annual HealthCONx Conference

Brookfield Asset Management Reinsurance Partners Ltd

Kyndryl Holdings

Spin-off stocks can be lucrative for shareholders in both legacy businesses and recently created public companies. Here are three to know.

3 Recent Spin-Off Stocks Worth A Spot in Your Portfolio

Accenture Plc

NEW YORK--(BUSINESS WIRE)--Accenture was selected by Organon to transform the company's enterprise resource planning technology into a cloud-based digital core.

Accenture and Organon Team Up to Drive Digital Transformation for Better Patient and Employee Experiences

Bristol-Myers

Chevron

Floor & Decor Holdings

Marsh & McLennan

Merck

Royalty Pharma

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its third-quarter 13F filing earlier this week, reporting U.S. equity position changes during the three months to the end of September.

Buffett Continues to Sell Stock as Turnover Increases

AbbVie

Charter Communications

Liberty Global Ltd

Liberty Media Corp-Liberty SiriusXM

Mastercard

U.S. Bancorp

Visa

Berkshire Hathaway CEO Warren Buffett kept up his bearish streak in Q3 2021, but he did add a pair of positions from two of his favored industries.

10 Stocks Warren Buffett Is Selling (And 4 He's Buying)

Organon was formed via the spin-out of Merck's Women's Health, Biosimilars and Established Brands divisions - shares began trading in May. On Nov. 11, the company reported Q321 earnings, affirming FY21 guidance for $6.2-$6.3bn.

Organon: Post Earnings Dip Is A Buy Opportunity Based On Jaw-Dropping Fundamentals

Organon & Co. (OGN) CEO Kevin Ali on Q3 2021 Earnings Conference Call - Earnings Call Transcript

Organon's (OGN) earnings and revenues trump estimates in the third quarter of 2021. Shares down in pre-market trading.

Organon's (OGN) Earnings & Revenues Surpass Estimates in Q3

Shares of Organon & Co. OGN, -6.36% were down 6.7% in trading on Thursday after the company said it plans to acquire Forendo Pharma, a privately held company developing an endometriosis therapy. As part of the agreement, Organon will pay $75 million upfront, with an additional $879 million available in milestone payments.

Organon's stock slides after announcing deal with Forendo Pharma

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN) (the “company”), today announced its results for the third quarter and year to date ended September 30, 2021. Organon also announced that its Board of Directors declared a quarterly dividend of $0.28 for each issued and outstanding share of the company's common stock. The dividend is payable on December 16, 2021 to stockholders of record at the close of business on November 22, 2021. "Just months after becoming a standalone company, we are

Organon Reports Results for the Third Quarter Ended September 30, 2021

JERSEY CITY, N.J. & TURKU, Finland--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women's health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral 1

Organon to Acquire Forendo Pharma

Organon (OGN) is set to provide updates on its earnings and revenues when it reports third-quarter 2021 results.

Organon (OGN) to Report Q3 Earnings: What's in the Cards?

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), will release its third quarter 2021 financial results on November 11, 2021, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company's website. Inst

Organon To Report Third Quarter Results and Host Conference Call on November 11, 2021

Kraft Heinz

Coca-Cola

Mondelez

Sirius XM Holdings Inc

STORE Capital

Verizon

This Buffett holdings list from Kiplinger first appeared 8/17/21 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 10/13/21 YCharts data.

News for Organon & Co Stock (OGN)